echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ASCO 2020 . . . Upstart: Targeting PD-L1 precursor therapy drug CX-072

    ASCO 2020 . . . Upstart: Targeting PD-L1 precursor therapy drug CX-072

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    This year ASCO's new PD-L1 antibody data code-named CX-072 was released, from the results of the study, its safety is excellent, more intimate is the target PD-L1 precursor treatment drug CX-072 "instruction" also appeared in the ASCO wall report, then we have a good understanding of this post-riseIn phase I/II trials, evidence of intratumor localization, activation, and immunomodulation of the precursor therapy drug CX-072 targeted at PD-L1BACKGROUND: PROBODY Therapy (Pb Tx) is a shielded antibody that selectively activates tumor microenvironments through tumor-related proteases and remains mostly inactive in normal tissuesThe CX-072 is APb-Tx for PD-L1 and is designed to reduce the likelihood of immune-related adverse events in normal tissues while maintaining antitumor activityThe CX-072 is under study in THE PR-CX-072 (NCT03013491), the first human phase I/II trialCX-072 is given to patients with metastatic or recurrent solid or lymphomas with single drugs or in combination with epipimo, who do not have approved treatment based on PD-1 / -L1We provide the latest results of tissue-based biomarker studies designed to assess the activation, positioning and action mechanisms of CX-072 in patient tumorsMethods: Tumor biopsies were collected 3 to 5 days after the screening stage and the first or third dose of 0.3 to 30 mg / kg CX-072Tumor-related protease activity was determined by tissue enzyme spectrometryThe activation of CX-072 in the tumor was measured using capillary immunoradiosis and the level of PD-L1 was measured with ultra-sensitive ELISAUse immunohistochemical analysis of cd8 expression in tumorsThe complete total CX-072 in the plasma is measured by LC-MS/MSResults: In 30 assessable pre-drug biopsies, 26 (87%) had detectable levels of associated protease activityIntra-tumor activation of CX-072 can be quantified in 3 of 8 biopsies (38%) (treated at 3 mg/kg dose) and 12 (100%) biopsies (treated at 10 mg/kg)In contrast, the CX-072 remains in full form in the loopThe muryl ratio of CX-072 in tumors activated in patients with a dose of 10 mg / kg was in the range of ?14x to 100x, and the calculated tumor receptor occupancy of these patients was 99%, consistent with quantitative system pharmacology model prediction The increase in CD8 plus was consistent with the inhibition of the PD-L1 pathway in 11 (61%) tumors in 18 cases of CX-072 single drug treatment Conclusion: These results show that Pb Tx CX-072 performed in patients in line with the design PL-CX-072: Analysis of patients with advanced solid tumors who received PD-L1 antibody precursor therapy drug CX-072 as a single drug or in combination with ipilimumab BACKGROUND: Single therapy for immunocheckpoint inhibitors (ICIs) has been shown to be effective in many cancers The combined use of ICIs PD-L1 and CTLA-4 is more effective but more toxic than single-drug therapy, and therefore, despite the dose-response effects of the drug, ctLA-4 doses are often adjusted CX-072 is a research PD-L1 antibody therapy that can be activated first in tumor microenvironments (TME); THE EPS-CX-072-001 IDENTIFIED 10 MG / KG Q2W (Mono10) as the recommended single therapy dose Here, we provide data on the increasing dose of Mono10 and CX-072 combined with IPI (Combo), with a focus on long-term treatment Methods: Mono10 was evaluated in a variety of tumor types The combined dose of Q3W assessment is CX-072 0.3 to 10 mg / kg and IPI 3 to 10 mg / kg Compare patients with treatment duration of 6 mo (-6M-TD) as of November 30, 2019 Results: The disease control rate (DCR-CR-PR-SD) mono10 was 41% (n-47/114; 10 PRs) and Combo were 37% (n-10/27; 1CR-4 PRs (1CR/kg IPI at 1CR and 3P (IPI3)
    The RESULTs of the PL-CX-072 study did not result in death from adverse events (TRAE) associated with treatment The most common stop-and-go (dc) cause in all groups was disease progression Conclusion : CX-072 monotherapy showed a long-lasting response, consistent with the activation of PROBODY therapy in TME The safety profile supports CX-072 as a monotherapy and tolerance when combined with IPI3 CX-072 plus IPI3 showed activity in highly pretreated patients with multiple tumors The CX-072 and IPI3 combinations are more secure than historical data (the ratio of a rating of 3 is 55%, resulting in 36% dc) Author: Ren Ran Source: Health
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.